Registered with the international EPD platform "EPD-Global"

HK Innoen's K-Cab Tab 50mg, a treatment for esophageal reflux disease, has become the world's first oral finished pharmaceutical product to obtain an Environmental Product Declaration (EPD).


HK Innoen announced on September 7 that on September 2 (local time), it attended the EPD certificate presentation hosted jointly by EPD-Global and the International Green Sustainability Certification (IGSC) in Oslo, Norway, and received the EPD certificate for K-Cab Tab 50mg.

HK Innoen Esophageal Reflux Disease New Drug K-CAB Series. HK Innoen

HK Innoen Esophageal Reflux Disease New Drug K-CAB Series. HK Innoen

View original image

The EPD is a system that quantifies the environmental impact of a product from raw material production to manufacturing and distribution, according to international standards, and discloses the results after third-party verification.


The EPD for K-Cab Tab 50mg was registered with the international EPD platform, EPD-Global, in June. Before registration, the International Green Sustainability Certification (IGSC), a third-party verification body, conducted an independent review based on ISO 14025.


HK Innoen completed the Life Cycle Assessment (LCA) for K-Cab Tab 50mg according to ISO 14040 and ISO 14044 standards. This EPD covers all stages, from the production of active pharmaceutical ingredients to manufacturing, packaging, and distribution of the finished product.



A representative from HK Innoen stated, "Securing the EPD immediately after the establishment of pharmaceutical LCA standards is a significant ESG (environmental, social, and governance) achievement in the industry. We plan to expand environmental assessment to major products and further advance our environmental information management system across our entire product portfolio."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing